Page 6 of 9, showing 50 records out of 402 total, starting on record 251, ending on 300
| Publication |
Category |
Year |
|
152. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. |
Intracrinology |
1998 |
|
151. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguère, V. (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β. Endocrinology, 139: 111-118. |
Intracrinology |
1998 |
|
150. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1998) Ligand-independent activation of the estrogen receptors α and β by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res., 58: 877-881. |
Intracrinology |
1998 |
|
149. Labrie, F. (1998) DHEA as physiological replacement therapy at menopause. J. Endocrinol. Invest., 21: 399-401. |
Intracrinology |
1998 |
|
148. Sourla, A., Flamand, M., Bélanger, A., Labrie, F. (1998) Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. J. Steroid Biochem. Mol. Biol., 66: 137-149. |
Intracrinology |
1998 |
|
147. Coquet, A., Boudreau, N., Merand, Y., Labrie, F. (1998) Validated high-performance liquid chromatographic methods for quantitation of a novel nonsteroidal antiestrogen. J. Chromatogr. A, 828: 247-258. |
Intracrinology |
1998 |
|
146. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. |
Intracrinology |
1999 |
|
145. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. |
Intracrinology |
1999 |
|
144. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. |
Intracrinology |
1999 |
|
143. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
Intracrinology |
1999 |
|
142. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. |
Intracrinology |
1999 |
|
141. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. |
Intracrinology |
1999 |
|
140. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum. Pathol., 30: 1503-1507. |
Intracrinology |
1999 |
|
139. van der Kwast, T.H., Têtu, B., Candas, B., Gomez, J.-L., Cusan, L., Labrie, F. (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology, 53: 523-529. |
Intracrinology |
1999 |
|
138. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. |
Intracrinology |
1999 |
|
137. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. |
Intracrinology |
1999 |
|
136. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. |
Intracrinology |
1999 |
|
135. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. |
Intracrinology |
1999 |
|
134. Pelletier, G., Luu-The, V., Charbonneau, A., Labrie, F. (1999) Cellular localization of estrogen receptor beta messenger ribonucleic acid in cynomolgus monkey reproductive organs. Biol. Reprod., 61: 1249-1255. |
Intracrinology |
1999 |
|
133. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α⁄β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. |
Intracrinology |
1999 |
|
132. Labrie, F. (1999) Potential of DHEA as hormone replacement therapy, in Reproductive Medicine: Past Present and Future. Proceeding of the 10th World Congress on Human Reproduction, Salvador, Bahia, Brazil, Parthenon Publishing, pp 224-237. |
Intracrinology |
1999 |
|
131. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (1999) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, New York, Walter de Gruyter, pp 299-342. |
Intracrinology |
1999 |
|
130. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Lin, S.-X., Cusan, L., Labrie, C. (1999) Role of DHEA transformation into androgens and estrogens in peripheral intracrine tissues, in: Thijssen, J.H.H. et Nieuwenhuyse, H., eds: DHEA a comprehensive review (Proceedings Workshop, Amsterdam 1997), New York, Parthenon Publishing, pp 69-103. |
Intracrinology |
1999 |
|
129. Tchernof, A., Labrie, F., Després, J.P. (1999) DHEA, obesity and cardiovascular disease, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, Walter de Gruyter, pp 191-213. |
Intracrinology |
1999 |
|
128. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17β-hydroxysteroid dehydrogenase, 3 β-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. |
Intracrinology |
1999 |
|
127. Labrie, F. (1999) Internal symposium: Editorial. Xth International Congress on Hormonal Steroids (Quebec City, Canada 17-21 June 1998). J. Steroid Biochem. Mol. Biol., 69: 1. |
Intracrinology |
1999 |
|
126. Labrie, F., Simard, J., Pasqualini, J.R. (1999) Potential of DHEA as hormonal replacement therapy, 486 pages. |
Intracrinology |
1999 |
|
125. Tremblay, A., Tremblay, G.B., Labrie, F., Giguère, V. (1999) Ligand-independent recruitment of SRC-1 to estrogen receptor Beta through phosphorylation of activation function AF-1. Mol. Cell., 3: 513-519. |
Intracrinology |
1999 |
|
124. Tremblay, M.R., Luu-The, V., Leblanc, G., Noël, P., Breton, E., Labrie, F., Poirier, D. (1999) Spironolactone-related inhibitors of type II 17Beta-hydroxysteroid dehydrogenase: Chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Bioorg. Med. Chem., 7: 1013-1023. |
Intracrinology |
1999 |
|
123. Zhu, D.-W., Campbell, R., Labrie, F., Lin, S.-X. (1999) Crystallization and preliminary crystal structure of the complex of 17Beta-hydroxysteroid dehydrogenase with a dual-site inhibitor. J. Steroid Biochem. Mol. Biol., 70: 229-235. |
Intracrinology |
1999 |
|
122. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. |
Intracrinology |
1999 |
|
121. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. |
Intracrinology |
2000 |
|
120. Labrie, F., Candas, B. (2000) Androgen blockade in prostate cancer [Letter-to-the-Editor]. Lancet, 356: 341-342. |
Intracrinology |
2000 |
|
119. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. |
Intracrinology |
2000 |
|
118. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. |
Intracrinology |
2000 |
|
117. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor β and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. |
Intracrinology |
2000 |
|
116. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. |
Intracrinology |
2000 |
|
115. Labrie, F., Luu-The, V., Labrie, C., Pelletier, G., El Alfy, M. (2000) Intracrinology and the skin. Horm. Res., 54: 218-229. |
Intracrinology |
2000 |
|
114. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. |
Intracrinology |
2000 |
|
113. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. |
Intracrinology |
2000 |
|
112. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. |
Intracrinology |
2000 |
|
111. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. |
Intracrinology |
2000 |
|
110. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. |
Intracrinology |
2000 |
|
109. Boivin, R.P., Luu-The, V., Lachance, R., Labrie, F., Poirier, D. (2000) Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase. J. Med. Chem., 43: 4465-4478. |
Intracrinology |
2000 |
|
108. Mauriège, P., Langin, D., Montminy, V., Martel, C., Després, J.P., Bélanger, A., Labrie, F., Deshaies, Y. (2000) Effect of a long-term percutaneous adrenal steroid treatment on rat adipose tissue metabolism. Int. J. Obes. Relat. Metab. Disord., 24: S148-S150. |
Intracrinology |
2000 |
|
107. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (2000) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: (DHEA): Biochemical Physiological and Clinical Aspects, pp 191-213. |
Intracrinology |
2000 |
|
106. Sam, K.-M., Labrie, F., Poirier, D. (2000) N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17β-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur. J. Med. Chem., 35: 217-225. |
Intracrinology |
2000 |
|
105. Singh, S.M., Gauthier, S., Labrie, F. (2000) Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem., 7: 211-247. |
Intracrinology |
2000 |
|
104. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
Intracrinology |
2001 |
|
103. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
Intracrinology |
2001 |